• ASBMB 2016 Annual Meeting

Sickle Cell Disease Severity

SEBM/EBM Symposium 2016
      Guest Society of the American Society of Biochemistry and Molecular Biology

Symposium Organizers: Steven R. Goodman, PhD and Betty S. Pace, MD
Monday, April 4, 2016, 3:00PM - 5:30PM
San Diego Convention Center, Room 6A

Classical homozygous (SS) Sickle Cell Anemia (SCA) is the most prevalent form of Sickle Cell Disease (SCD). It is a monogenic hemoglobinopathy yet it has great variation in the clinical severity and outcome. Many SCA patients have a mild clinical course sometimes living into their 60’s and 70’s; while others have a much more severe clinical course with multiple crises per year, significant organ damage and a shortened life span. An understanding of this variability in severity and outcome has been the focus of many laboratories as it would lead to improved therapeutics and biomarkers which could allow the development of personalized medicine for people with SCA. This Symposium will provide the audience with the current understanding of the molecular bases for the variability of sickle cell severity and current treatment for SCD patients.

Invited Speakers

     Charles Quinn, MD, “Clinical severity in sickle cell disease: definitions and prognostication”

     Vivian Sheehan, MD/PhD, "Rheological Abnormalities of Pediatric Hemoglobin SC Patients"

     Martin Steinberg, MD, “Genetic Basis of HbF Variability in Sickle Cell Anemia; A Global Perspective”

     Winfred Wang, MD, “Is Hydroxyurea Efficacious in Both Severe and Non-Severe Sickle Cell Disease?”